Michael T. Lotze, MD, is professor of surgery, immunology and bioengineering at the University of Pittsburgh School of Medicine. Dr. Lotze received his MD and PhD degrees from Northwestern University. Except for a two-year period at GlaxoSmithKline, King of Prussia, PA, and a dozen years on the senior staff at the National Cancer Institute in Bethesda, MD, Dr. Lotze has done his work at the University of Pittsburgh. 

Dr. Lotze serves as associate editor of the Journal of Immunotherapy and Oncology and in 2024 became the editor in chief of the Society for Immunotherapy of Cancer’s official journal, the Journal of ImmunoTherapy of Cancer. He initiated the first approved gene therapy protocols at the NIH and has treated more than 100 patients on gene therapy protocols at the University of Pittsburgh. He is the co-inventor of 10 patents in dendritic cell vaccines and antigen discovery, and author of more than 500 scientific papers and chapters in basic and applied tumor immunology and cytokine biology. 

Currently, Dr. Lotze is the leader in the area of exploring cancer as a disorder of cell death and is devising novel strategies to approach the disease in this context.